Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A **combination allergenic extract** composed of pollen from *Ambrosia trifida* and *Ambrosia artemisiifolia* used in allergen immunotherapy and diagnostic allergy testing for ragweed sensitization. This product is marketed as a non-standardized biologic allergen extract for **skin test diagnosis** in patients with a clinical history of ragweed allergy and, after dilution, for **subcutaneous immunotherapy**. Its therapeutic effect is based on controlled exposure to ragweed allergens to modulate the allergic immune response, while its diagnostic use relies on provoking an IgE-mediated hypersensitivity response in sensitized individuals. The product has been marketed by Greer Laboratories and is distinct from the approved sublingual short ragweed tablet product that contains only *Ambrosia artemisiifolia*.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ambrosia trifida pollen + ambrosia artemisiifolia pollen.